卫光生物(002880.SZ)发布上半年业绩，归母净利润1.08亿元，下降2.02%

Core Viewpoint - Weigao Bio (002880.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 518 million yuan, a year-on-year decrease of 0.92% [1] - The net profit attributable to shareholders of the listed company was 108 million yuan, reflecting a year-on-year decrease of 2.02% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 106 million yuan, down 1.36% year-on-year [1] - Basic earnings per share were reported at 0.4746 yuan [1]